Aptevo Therapeutics Inc.
As of Oct 22, 2026, Aptevo Therapeutics is in Stage 4, the downtrend phase, now in week 15 (since Jul 9, 2026). It closed at $1.61, 94.3% below its 52-week high and below its 200-day average, which is falling.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is APVO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
APVO among Biotechnology530th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …530 | APVO | Stage 4 · wk 15 | 5 | −14.8% |
Aptevo Therapeutics: quick answers
What stage is Aptevo Therapeutics in?
As of Oct 22, 2026, Aptevo Therapeutics (APVO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 9, 2026 and is in week 15. What the four stages mean
Is Aptevo Therapeutics in an uptrend?
No. Aptevo Therapeutics is in a Stage 4 downtrend. It trades 65.0% below its 200-day average, which is falling.
How far is Aptevo Therapeutics from its 52-week high?
Aptevo Therapeutics closed at $1.61 on Oct 22, 2026, 94.3% below its 52-week high of $28.08. Its 52-week low is $1.60.
How has Aptevo Therapeutics performed over the past year?
As of Oct 22, 2026, Aptevo Therapeutics is down 94.3% over the past year and down 82.9% so far in 2026.
Which sector and industry is Aptevo Therapeutics in?
Aptevo Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.